Alpha Teknova Earnings Call Transcripts
Fiscal Year 2026
-
The company highlighted record revenue growth, improved profitability metrics, and raised guidance, driven by strong demand in biopharma and diagnostics. Strategic investments in AI, commercial capabilities, and potential acquisitions position it for continued expansion, with EBITDA and cash flow positivity targeted by 2027.
-
Record Q2 2026 revenue grew 18% year-over-year, driven by broad-based demand except for cell and gene therapy. Raised 2026 revenue guidance to $45–$47M, launched Build-Tek AI configurator, and expect commercial investments to drive further growth in 2027.
-
Q1 2026 saw 13% revenue growth, led by an 85% surge in Clinical Solutions and improved gross margin. Investments in commercial capabilities and automation are expected to drive double-digit growth in 2027, with positive adjusted EBITDA targeted by year-end 2027.
-
Revenue reached $40.5 million in 2025 with strong growth in both catalog and custom GMP products. Investments in sales, marketing, and technology, along with a new GMP facility, position the business for profitability by 2027. Clinical Solutions and Lab Essentials segments drive future upside as therapies advance through clinical stages.
Fiscal Year 2025
-
Revenue grew 7% in 2025 with improved gross margins and reduced losses. Investments in commercial capabilities and a recovering biotech market are expected to drive future growth, with positive adjusted EBITDA targeted by end of 2027.
-
Q3 2025 saw 9% revenue growth and improved gross margins, led by strong Lab Essentials sales, while Clinical Solutions revenue declined. The outlook remains cautious for biopharma custom products, but double-digit growth continues in other segments. Guidance for 2025 revenue is $39–$42 million, with no need for additional capital.
-
Q2 2025 saw 7% revenue growth, strong catalog sales, and improved gross margin to 38.7%. Clinical Solutions revenue rose 32% YoY, while guidance for 2025 was reiterated at $39–$42 million. Operational efficiencies and a growing customer base support long-term growth.
-
Custom and catalog reagent provider leverages recent infrastructure investments to scale rapidly, targeting 20%-25% growth and higher margins. Strong customer retention, fast turnaround, and new partnerships position the business for long-term profitability and expansion.
-
Q1 2025 revenue grew 5% year-over-year to $9.8M, with strong catalog product growth and improved gross margin. Guidance for 2025 was reiterated, expecting 7% revenue growth and continued margin improvement, while a new collaboration with Pluristyx expands the product portfolio.
Fiscal Year 2024
-
2024 saw revenue growth, improved cash flow, and reduced expenses, with strong gains in clinical and biopharma segments. 2025 guidance anticipates 7% revenue growth, margin expansion, and continued cost discipline amid cautious customer spending and macro uncertainty.
-
The company has stabilized after a challenging period, with strong growth in its catalog business and expanding clinical customer base. New offerings like Express-Tek and RUO+ are gaining traction, and cost reductions have positioned the business for profitability. Long-term growth targets remain ambitious, with a focus on innovation and operational efficiency.
-
Q3 2024 saw 17% revenue growth year-over-year, driven by biopharma custom product sales and increased clinical customer count. Gross margin was impacted by a $2.8M inventory write-down, but cost controls led to the lowest free cash outflow in three years. 2024 revenue guidance is flat, with liquidity sufficient to reach profitability.
-
A custom reagents provider is leveraging a new GMP-certified facility, proprietary product launches, and a focused commercial strategy to drive growth, especially in cell and gene therapy. Financial targets include breakeven at $50–$55M revenue, with recent funding expected to support the path to profitability.
-
Q2 2024 revenue was $9.6M, down 17% year-over-year but up 3% sequentially, with underlying growth of 9% excluding a large prior-year order. New product launches and increased clinical customer count support a positive outlook, and a $15.4M capital raise strengthens liquidity. Guidance for 2024 is reaffirmed, with double-digit growth expected in the second half.